eFinder

eFinder

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies



info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.